Astellas Pharma US | Changing Tomorrow | Home

Previous Pause Next

Diversity & Inclusion

Diversity & Inclusion at Astellas

Hear from our employees about the importance of Diversity & Inclusion

Astellas' Chelsea Glinski Named a 2019 Healthcare Businesswomen's Association Luminary

Astellas' Chelsea Glinski Named a 2019 Healthcare Businesswomen's Association Luminary

Astellas' Chelsea Glinski Named a 2019 Healthcare Businesswomen's Association Luminary

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer Read More

1

2

3

News

Latest

News / Media

May 31, 2019

U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA^® (gilteritinib)

News / Media

Apr 25, 2019

Changes of Representative Director and Directors

News / Media

Apr 25, 2019

Changes of Representative Director and Directors

News / Corporate

Jun 03, 2019

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer

News / Corporate

May 30, 2019

U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib)

News / Corporate

May 20, 2019

Astellas Oncology Announces C³ Prize® Call for Entries to Award $200,000 to the Best Ideas in Cancer Care Beyond Medicine